The Amyloid-β Pathway in Alzheimer’s Disease

Амилоид-β-путь при болезни Альцгеймера
George L. Perry, John Hardy, Harald Juergen Hampel, Kaj Blennow, Colin Louis Masters, Andrea Vergallo, Jeffrey L. Cummings, Christopher Chen, Seung Hyun Kim, Victor L. Villemagne, Paul S. S. Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Min Cho, Lars Lannfelt
2021-08-29

Alzheimer’s diseaseAβ dyshomeostasisAβ-targeting therapiesamyloid-β pathwaymultimodal biomarkers
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established biochemical alterations of the Aβ cycle remain the core biological hallmark of AD and are promising targets for the development of disease-modifying therapies. Here, we systematically review and update the vast state-of-the-art literature of Aβ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of Aβ pathway dyshomeostasis in AD pathophysiological dynamics. We discuss the evidence highlighting a differentiated interaction of distinct Aβ species with other AD-related biological mechanisms, such as tau-mediated, neuroimmune and inflammatory changes, as well as a neurochemical imbalance. Through the lens of the latest development of multimodal in vivo biomarkers of AD, this cross-disciplinary review examines the compelling hypothesis- and data-driven rationale for Aβ-targeting therapeutic strategies in development for the early treatment of AD.
1
Although the molecular and spatiotemporal mechanisms linking Aβ alterations to synaptic failure and neurodegeneration remain incompletely resolved, Aβ-targeting strategies are supported for early Alzheimer’s treatment.
2
Basic research, human genetic studies, and multimodal biomarker evidence support a crucial role for Aβ pathway dyshomeostasis in Alzheimer’s pathophysiology.
3
Distinct Aβ species interact differentially with tau-mediated processes, neuroimmune and inflammatory changes, and neurochemical imbalance.
4
The amyloid-β (Aβ) pathway is identified as a central biological hallmark of Alzheimer’s disease and a promising target for disease-modifying therapies.

the amyloid-β (Aβ) pathway in Alzheimer’s disease

the pathway’s biochemical dyshomeostasis, molecular dynamics, and interactions with tau, neuroimmune and inflammatory mechanisms, and neurochemical balance in AD pathophysiology

Publication Details
Publication Date
2021-08-29
Journal
Publisher
ISSN
Cited by
2011
Access Type
Author Information
Authors
George L. Perry
John Hardy
Harald Juergen Hampel
Kaj Blennow
Colin Louis Masters
Andrea Vergallo
Jeffrey L. Cummings
Christopher Chen
Seung Hyun Kim
Victor L. Villemagne
Paul S. S. Aisen
Michele Vendruscolo
Takeshi Iwatsubo
Min Cho
Lars Lannfelt
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%